Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...
Main Authors: | Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou, Meletios A. Dimopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620721989586 |
Similar Items
-
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01) -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
by: Maddalena Mazzucchelli, et al.
Published: (2018-01-01) -
Pseudohyperphosphatemia in Waldenstrom′s Macroglobulinemia
by: S D Amalnath, et al.
Published: (2013-01-01) -
Diagnóstico presuntivo de la macroglobulinemia de Waldenström Presumptive diagnosis of the macroglobulinemia of Waldenström
by: Ana Dolores Izquierdo Calzado
Published: (2012-04-01) -
Cutaneous macroglobulinosis with Waldenström macroglobulinemia
by: Hussein M.M. Hassab-El-Naby, MD, et al.
Published: (2020-08-01)